ISSN:
1365-2036
Source:
Blackwell Publishing Journal Backfiles 1879-2005
Topics:
Medicine
Notes:
Our previous study demonstrated that Helicobacter pylori eradication was less effective in smokers than in non-smokers. Cetraxate is an anti-ulcer drug that increases gastric mucosal blood flow.〈section xml:id="abs1-2"〉〈title type="main"〉Aim:To evaluate the effect of cetraxate combined with new triple therapy for the eradication of H. pylori in smokers.〈section xml:id="abs1-3"〉〈title type="main"〉Methods:This study had a single-centre, double-blind, randomized non-placebo design. A total of 106 consecutive H. pylori-positive smoking patients were randomly allocated to one of two regimens: one group received omeprazole (20 mg), amoxycillin (1500 mg), and clarithromycin (600 mg) for 7 days (OAC, n=55). The other group recieved OAC plus cetraxate (600 mg) for 7 days (OAC + CET, n=51). The success of H. pylori eradication was evaluated by histology and the 13C-urea breath test at 4 weeks after completion of treatment.〈section xml:id="abs1-4"〉〈title type="main"〉Results:By intention-to-treat analysis, the H. pylori eradication rate was 55% in the OAC group and 92% in the OAC + CET group (P 〈 0.01). By per protocol analysis, the H. pylori eradication rate was 58% in the OAC group and 94% in the OAC + CET group (P 〈 0.01).〈section xml:id="abs1-5"〉〈title type="main"〉Conclusion:Cetraxate combined with new triple therapy increases the eradication of H. pylori in smokers.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1046/j.1365-2036.2000.00807.x
